Celgene Corporation

Jefferies reiterates Buy on Celgene Corporation (NASDAQ: CELG). In a research report published today, Jefferies commented on the company's Revlimid product. In the report, Jefferies states, "While we agree with the Street that an increase in protocol-specified Revlimid maintenance duration in the...

According to a recent report from Jefferies, after speaking with 11 hematologists at the EHA meeting in London, Jefferies believes that the opinion of European physicians has turned positive on Revlimid maintenance and Celgene (NASDAQ: CELG). In the report, Jefferies said, "Of the 11 hematologists...

JP Morgan has raised the price target on Celgene (NASDAQ: CELG) from $65 to $70 and maintains its Overweight rating.

Morgan Stanley is raising its PT on share of Celgene Corporation (NASDAQ: CELG) to $55. Celgene Corporation closed Monday at $59.78.

Celgene Corporation (NASDAQ: CELG) reiterated its '15 guidance of $8B in total revs & $8 in EPS, Deutsche Bank reports. “The company sees $6-6.5B revs coming from hematology business,” Deutsche Bank writes. “Revlimid will contribute towards 70%-80% of hematology sales. Abraxane '15 sales are...

Jefferies is maintaining its Buy rating and its $68 price target on Celgene Corp. (NASDAQ: CELG) in advance of a full update of its IFM study, to be released this Thursday. Says Jefferies, in its report, “We believe the updated count of second primary malignancies (SPMs) in the French IFM study of...

Yesterday, J.P. Morgan hosted a “productive lunch with Celgene Corporation (NASDAQ: CELG) management where the topics discussed included the impact of donut hole accounting for Revlimid, what to expect at upcoming medical meetings, and the company's long-term growth prospects.” “Overall, we remain...

Citi Reports Consensus Estimates For Revlimid Are Fine For Celgene, Even With Donut Hole Hit In a report published by Citi, Celgene Corp (NASDAQ: CELG) expects to hear from its auditor in the next few weeks regarding amortization of Medicare's donut hole exp as part of the HC reform provision that...

Piper Jaffray has raised the price target on Celgene Corporation (NASDAQ: CELG) from $81 to $82 and maintains its Overweight rating.

Wells Fargo is resuming coverage on Celgene Corporation (NASDAQ: CELG) with a change in analyst, an Outperform rating on the shares, and a $65-$69 valuation range. “We are enthusiastic for Revlimid's future prospects, with the likely label expansion and paradigm shift toward maintenance use helping...

On the cusp of the 3Q10 earnings season for biotechnology, J.P. Morgan is providing an overview of the companies within the industry. This quarter, Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Celgene Corporation (NASDAQ: CELG) are the leaders of the pack. “We are modestly raising our Revlimid...